Guidance and quality standards Awaiting development

Showing 271 to 280 of 289

Guidance and quality standards awaiting development
Title	Type
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance
Venglustat for treating gangliosidoses in people 2 years and over [ID6358]	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TS ID 11950	Technology appraisal guidance
Vilobelimab for treating COVID 19 TS ID 11815	Technology appraisal guidance
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable TS ID 10266	Technology appraisal guidance
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over TS ID 11974	Technology appraisal guidance
Vosoritide for treating achondroplasia in children TSID 12001	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467	Technology appraisal guidance